# Superselective Adrenal Arterial Embolization for Resistant Hypertension

> **NCT05552300** · NA · UNKNOWN · sponsor: **First Affiliated Hospital of Chengdu Medical College** · enrollment: 144 (estimated)

## Conditions studied

- Resistant Hypertension

## Interventions

- **PROCEDURE:** SAAE
- **DRUG:** traditional triple antihypertensive treatment

## Key facts

- **NCT ID:** NCT05552300
- **Lead sponsor:** First Affiliated Hospital of Chengdu Medical College
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2024-10-01
- **Final completion:** 2025-03-31
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2022-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05552300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05552300, "Superselective Adrenal Arterial Embolization for Resistant Hypertension". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT05552300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*